Bristol-Myers Squibb (NYSE:BMY) Stock Holdings Lowered by Great Lakes Advisors LLC

Great Lakes Advisors LLC decreased its holdings in Bristol-Myers Squibb (NYSE:BMY) by 48.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,575 shares of the biopharmaceutical company’s stock after selling 9,795 shares during the quarter. Great Lakes Advisors LLC’s holdings in Bristol-Myers Squibb were worth $598,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Truvestments Capital LLC boosted its stake in shares of Bristol-Myers Squibb by 9.3% during the 4th quarter. Truvestments Capital LLC now owns 6,802 shares of the biopharmaceutical company’s stock worth $385,000 after acquiring an additional 581 shares in the last quarter. Hopwood Financial Services Inc. purchased a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at $85,000. EverSource Wealth Advisors LLC boosted its position in shares of Bristol-Myers Squibb by 15.4% in the 4th quarter. EverSource Wealth Advisors LLC now owns 7,604 shares of the biopharmaceutical company’s stock valued at $430,000 after purchasing an additional 1,015 shares during the period. Sequoia Financial Advisors LLC increased its stake in Bristol-Myers Squibb by 6.1% in the 4th quarter. Sequoia Financial Advisors LLC now owns 151,700 shares of the biopharmaceutical company’s stock worth $8,580,000 after purchasing an additional 8,745 shares in the last quarter. Finally, Moors & Cabot Inc. raised its holdings in Bristol-Myers Squibb by 14.9% during the 4th quarter. Moors & Cabot Inc. now owns 89,229 shares of the biopharmaceutical company’s stock worth $5,047,000 after buying an additional 11,578 shares during the period. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Down 2.1 %

Shares of BMY stock opened at $59.01 on Monday. The business’s 50 day moving average is $57.81 and its two-hundred day moving average is $55.61. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33. The company has a market cap of $119.75 billion, a PE ratio of -13.35, a price-to-earnings-growth ratio of 2.07 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. Equities analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 4.20%. The ex-dividend date is Friday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -56.11%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on BMY. Jefferies Financial Group upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and raised their target price for the stock from $63.00 to $70.00 in a report on Monday, December 16th. Wells Fargo & Company raised their price objective on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a research note on Friday, February 7th. Bank of America reissued a “neutral” rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Citigroup raised their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. Finally, Truist Financial upped their price target on Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $57.86.

Insiders Place Their Bets

In related news, EVP Samit Hirawat acquired 1,823 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was acquired at an average price of $54.84 per share, with a total value of $99,973.32. Following the completion of the transaction, the executive vice president now owns 63,932 shares of the company’s stock, valued at approximately $3,506,030.88. This represents a 2.94 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.09% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.